A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

Trial Profile

A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Degarelix (Primary) ; Letrozole; Triptorelin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TREND
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 May 2017 Planned End Date changed from 1 Sep 2021 to 1 Aug 2017.
    • 29 May 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top